Bright Minds Biosciences's book value per share for the quarter that ended in Mar. 2026 was $22.92.
During the past 12 months, Bright Minds Biosciences's average Book Value Per Share Growth Rate was 777.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 53.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 27.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Bright Minds Biosciences was 53.00% per year. The lowest was -46.90% per year. And the median was 45.40% per year.
During the past 6 years, the highest P/B Ratio of Bright Minds Biosciences was 3.03. The lowest was 0.00. And the median was 0.00.
Bright Minds Biosciences (NAS:DRUG) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Bright Minds Biosciences Book Value per Share Related Terms
Bright Minds Biosciences Book Value per Share Historical Data
* Premium members only.
The historical data trend for Bright Minds Biosciences's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bright Minds Biosciences Book Value per Share Chart
DRUG vs VRTX, REGN, ALNY: Book Value per Share Comparison
For the Biotechnology subindustry, Bright Minds Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bright Minds Biosciences PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bright Minds Biosciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Bright Minds Biosciences's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bright Minds Biosciences (DRUG) has a Book Value per Share of $22.92 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Bright Minds Biosciences and its competitors.
Is Bright Minds Biosciences' Book Value per Share too high?
Bright Minds Biosciences' current Book Value per Share is $22.92. Overall, Bright Minds Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Bright Minds Biosciences' Book Value per Share compare to VRTX and REGN?
Bright Minds Biosciences' Book Value per Share of $22.92 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Bright Minds Biosciences and its competitors. Bright Minds Biosciences's current Book Value per Share is $22.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bright Minds Biosciences stock overvalued right now?
Bright Minds Biosciences (DRUG) has a current Book Value per Share of $22.92. The current Book Value per Share is $22.92. Bright Minds Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Bright Minds Biosciences (DRUG), the current Book Value per Share is $22.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
34GF Score
Get the complete analysis for DRUG
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DRUG has been successfully added to your 
